Back to search

Aristotle University Of Thessaloniki (AUTH)

Μεταδιαφοροποιητικές και ανοσορρυθμιστικές ιδιότητες των μεσεγχυματικών κυττάρων του μυελού των οστών στην πειραματική αρθρίτιδα

Abstract

dc:description

The recently recognized potential of mesenchymal stromal cells (MSCs) to differentiate into a broad spectrum of tissues and to act as immune regulators has emerged intense research interest on their possible use in a wide range of clinical entities. Although the immunoregulatory potential of MSCs has been shown to effectively control Graft versus Host Disease (GvHD) in several clinical studies, their role in autoimmune diseases has not been extensively explored. It has been reported that MSCs can ameliorate autoimmune encephalomyelitis, lupus erythematosus, diabetes mellitus and autoimmune enteropathy in experimental models. However, their potential to treat rheumatoid arthritis (RA) has been thus far contradictory. The aim of the present thesis was to explore the effect of bone marrow MSCs in two animal models resembling human RA: adjuvant-induced arthritis (AIA) and spontaneously erosive arthritis (SEA). There was a clear discrepancy between the in vitro and in vivo immunosuppressive function of MSCs in AIA. In vitro, MSCs targeted two critical cell populations of RA: MSCs inhibited the proliferation of arthritic splenocytes (SPLCs) and the proliferation and invasiveness of arthritic fibroblast-like synoviocytes (FLS). In contrast, there was no clinical benefit when MSCs were administered in AIA, unless they were infused before the arthritis onset, an effect which cannot be clinically translated. Similarly, MSCs did not ameliorate SEA also, thus the hypothesis that TLR ligands present in the adjuvant used for arthritis induction potentially polarize MSCs towards a pro-inflammatory phenotype abrogating their immunomodulatory function, could not interpret their in vivo inefficiency. The observed discrepancy between the in vitro and in vivo function of MSCs strongly implicates the inflammatory microenvironment of arthritis as an inhibitory condition for the immunosuppressive effects of MSCs. An additional goal of this doctoral thesis was to investigate strategies which could overcome or attenuate the highly RA inflammatory milieu in order to circumvent the limitations of the in vivo MSC performance in RA. Towards this goal, we showed that cytokine- activated MSCs (either with IFN-γ or with combination of IFN-γ and TNF-α) were also ineffective in AIA. Subsequently, we investigated whether the proteasome inhibitor, Bortezomib (Bzb) which has been approved for clinical use in the treatment of multiple myeloma, could serve as a new therapeutic approach for RA. Bzb inhibits NF-κB and through it, important inflammatory mediators (TNF-α, IL-6, V-CAM-1), involved in inflammatory and autoimmune conditions such as RA. Our findings suggest that Bzb affects AIA in a pleiotropic manner. In vitro, Bzb exerted antiproliferative and proapoptotic effects in SPLCs and FLS from rats with AIA. In addition, Bzb reduced the invasiveness of FLS from rats with AIA and modified the pattern of cytokine secretion in cultured SPLCs. In vivo, Bzb markedly ameliorated AIA even when administered during advanced disease phase. The clinical remission was also histologically confirmed and it was associated with decreased T lymphocyte, B lymphocyte, and macrophage cell infiltration, decreased expression of cyclooxygenase 1 (COX-1) and reduced vessel density compared with control animals. Bzb improved bone disease in CT images and restored the increased expression of TLR-2, TLR-3 and TLR-4 in PB or in cultured FLS from treated animals. Although Bzb drastically affects AIA, the narrow therapeutic window observed in treated animals with AIA, the cytotoxicity of the drug at high concentrations and the need for repeated treatment in chronic diseases such as RA, raise safety concerns about its clinical use in RA. However, a short Bzb-course could temporarily alleviate the inflammatory milieu of experimental arthritis allowing MSCs to act immunosuppressively. Indeed, we demonstrated that Bzb+MSCs-treated animals presented significantly decreased clinical and histological arthritis score over AIA-, MSCs-alone- and Bzb-alone-treated animals. The Bzb+MSCs combination increased in vivo the blood T-regulatory cells (Tregs) and restored the proliferation and apoptosis of SPLCs, the cytokine secretion pattern in the supernatant of SPLCs and the expression of TLRs in blood. Conclusively, the results of this doctoral thesis suggest that MSCs could be effective in RA only under conditions that form a permissive microenvironment. In this setting, a short Bzb-course alters the inflammatory milieu of experimental arthritis allowing MSCs to exert their immunomodulatory function and significantly ameliorate the disease. It is our belief, that either Bzb or the combination of Bzb+MSCs are worth exploring in a clinical setting and that they potentially represent significant future treatment strategies for RA.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papadopoulou, Anastasia
  • Παπαδοπούλου, Αναστασία

Subjects

dc:subject × 12

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/33222

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papadopoulou, Anastasia; Παπαδοπούλου, Αναστασία. Μεταδιαφοροποιητικές και ανοσορρυθμιστικές ιδιότητες των μεσεγχυματικών κυττάρων του μυελού των οστών στην πειραματική αρθρίτιδα. Aristotle University Of Thessaloniki (AUTH), 2011. http://hdl.handle.net/10442/hedi/33222